Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
The bioconjugation suite will be located at its commercial biologics facility in Bengaluru, complementing commercial payload, linker and monoclonal antibodies services.
Syngene will offer fully integrated services for antibody-drug conjugates.
- Location: Bengaluru, India
- Facility: Commercial biologics facility [Unit 3]
- Services: End-to-end services for antibody-drug conjugates (ADCs)
Author's summary: Syngene International expands ADC capabilities.
More News
- Asian stocks climb after Wall Street rallies on hopes for lower interest rates
- Three key Vikings sidelined, including unexpected Adam Thielen absence
- Meet the new Bash Brothers — the 49ers have found a playoff-worthy safety duo in Mustapha and Brown
- Four Titans Officially Ruled Out for Week 13 Clash Against Jaguars
- Kurtenbach: The 49ers Are Battered, Bruised, and Extremely Dangerous Heading Into Their Bye Week
- Japan's same-sex marriage ban upheld
- Fan Mistakes Zach LaVine For Lonzo Ball; Reaction Priceless
- US stocks fall to their first loss in 6 days as bitcoin tumbles
- Sauce Gardner Injury Update: Colts Cornerback Out Against Texans
- Studs and Duds: Brock Purdy shines as 49ers defeat Browns